Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide

2 Nov 2018

Abstract excerpt

Glioblastoma (GBM) is a malignant, primary brain tumor, highly resistant to conventional therapies. Temozolomide (TMZ) is a first line therapeutic agent in GBM patients, however survival of such patients is poor. High level of DNA repair protein, O6-methylguanine-DNA-methyltransferase (MGMT) and occurrence of glioma stem-like cells contribute to GBM resistance to the drug. Here, we explored a possibility of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30450051
DOI: 10.3389/fphar.2018.01271

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to TemozolomidePMID 30450051Read ↗

BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cellsSemantic proximity Read ↗

Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaSemantic proximity Read ↗

PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomideSemantic proximity Read ↗

Unique Combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growthSemantic proximity Read ↗

How to train glioma cells to die: molecular challenges in cell deathSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read ↗

The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.Semantic proximity Read ↗

Induction Of XLF And 53BP1 Expression Is Associated With Temozolomide Resistance In Glioblastoma CellsSemantic proximity Read ↗

DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cellsSemantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.